Nanobiotix S.A. (NBTX)
| Market Cap | 459.70M |
| Revenue (ttm) | 2.38M |
| Net Income (ttm) | n/a |
| Shares Out | 34.83M |
| EPS (ttm) | -1.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 524 |
| Open | 12.40 |
| Previous Close | 13.04 |
| Day's Range | 12.52 - 13.20 |
| 52-Week Range | 10.51 - 21.55 |
| Beta | 2.28 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About NBTX
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. The company develops NanoXray products to help patients receiving radiotherapy by enhancing the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. It offers NBTXR3, a sterile aqueous suspension of functionalized crystalline hafnium oxide nanoparticles used for the treatment of solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pa...
Financial Performance
In 2020, Nanobiotix's revenue was 2.51 million, a decrease of -1.14% compared to the previous year's 2.54 million. Losses were -33.59 million, -34.03% less than in 2019.
Financial numbers in millions EURFinancial StatementsNews
NANOBIOTIX Provides Third Quarter Operational and Financial Update
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches ...
NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the ...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches ...
NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May “Reprogram” the Tum...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanophysics-based appro...
NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches...
Nanobiotix to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nanobiotix To Present at the 23rd Annual H.C. Wainwright Global Investment Conference
Nanobiotix Provides Second Quarter Operational and Financial Update
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Nanobiotix (Euronext: NANO – NASDAQ: NBTX) provides second quarter operational and financial update.
Nanobiotix Starts New NBTXR3 Study In Lung Cancer Patients
Nanobiotix (NASDAQ: NBTX) initiated a new Phase 1 study evaluating NBTXR3 activated by radiation therapy (RT) for patients with non-small cell lung cancer (NSCLC) amenable to re-irradiation. The study ...
NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering phy...
NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on Jun...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechno...
Nanobiotix's Nanoparticle Technology Shows Tumor-Killing Effect in Early-Stage Head & Neck Cancer
Nanobiotix (NASDAQ: NBTX), ahead of the 2021 Annual Meeting of the American Society for Clinical Oncology meeting, has said that its nanoparticles were able to shrink tumors in about 77% of patients in ...
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing L...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #ASCO--Regulatory News: NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-...
NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive Board t...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering phys...
NANOBIOTIX to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering phy...
Nanobiotix Announces the Appointment of Dr. Gary Phillips as Chairman of the Nanobiotix Supervisory Board
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering phy...
CORRECTING and REPLACING Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immu...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #ASCO--Regulatory News: Please replace the release dated May 19, 2021 with the following corrected version due to multiple revisions. NANOBIOTIX ANNOU...
Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential F...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #ASCO--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics...
Nanobiotix to Present at the UBS Global Healthcare Virtual Conference
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTX--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics...
Nanobiotix, LianBio Ink NBTXR3 Development Pact In Asia For Solid Tumor Settings
Nanobiotix (NASDAQ: NBTX) has announced a partnership with LianBio to develop and commercialize Nanobiotix's lead product candidate NBTXR3, in Greater China (mainland China, Hong Kong, Taiwan, and Macau...
NANOBIOTIX Announces First Quarter Operational and Financial Updates
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTX--Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology ...
NANOBIOTIX to Present Four Posters Including Updates From Priority Head and Neck Cancer and Immunotherapy Development...
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $NBTX #NBTXNews--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physi...
Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company'') (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneerin...
NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches ...
NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company'), a late-stage clinical biotechnology company pioneeri...
Nanobiotix, PharmaEngine Terminate Development Pact For Radiation Therapy In APAC Region
Nanobiotix (NASDAQ: NBTX) and PharmaEngine Inc have agreed to terminate the license and collaboration agreement announced in August 2012. The agreement provided PharmaEngine exclusive rights to further ...
NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News: NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a clinical-stage biotechnology company pioneering physics-based approaches to ...